Get access

CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges

Authors

  • Philipp Grosse-Gehling,

    1. Tumor Pathophysiology, OncoRay, National Center for Radiation Research in Oncology, Dresden University of Technology, Dresden, Germany
    Search for more papers by this author
  • Christine A Fargeas,

    1. Tissue Engineering Laboratories (BIOTEC) and DFG Research Center and Cluster of Excellence for Regenerative Therapies Dresden (CRTD), Dresden University of Technology, Dresden, Germany
    Search for more papers by this author
  • Claudia Dittfeld,

    1. Tumor Pathophysiology, OncoRay, National Center for Radiation Research in Oncology, Dresden University of Technology, Dresden, Germany
    Search for more papers by this author
  • Yvette Garbe,

    1. Tumor Pathophysiology, OncoRay, National Center for Radiation Research in Oncology, Dresden University of Technology, Dresden, Germany
    Search for more papers by this author
  • Malcolm R Alison,

    1. Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK
    Search for more papers by this author
  • Denis Corbeil,

    1. Tissue Engineering Laboratories (BIOTEC) and DFG Research Center and Cluster of Excellence for Regenerative Therapies Dresden (CRTD), Dresden University of Technology, Dresden, Germany
    Search for more papers by this author
  • Leoni A Kunz-Schughart

    Corresponding author
    • Tumor Pathophysiology, OncoRay, National Center for Radiation Research in Oncology, Dresden University of Technology, Dresden, Germany
    Search for more papers by this author

  • No conflicts of interest were declared.

Correspondence to: Professor Dr Leoni A Kunz-Schughart, OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstrasse 74, PF 41, 01307 Dresden, Germany. e-mail: leoni.kunz-schughart@oncoray.de

Abstract

The cancer stem cell (CSC) hypothesis, despite the limitations of the currently available models and assays, has ushered in a new era of excitement in cancer research. The development of novel strategies for anti-tumour therapy relies on the use of biomarkers to identify, enrich, and/or isolate the cell population(s) of interest. In this context, various cell characteristics and antigen expression profiles are discussed as surrogate markers. The cell surface expression of the human prominin-1 (CD133) antigen, in particular of the AC133 epitope, is among those that have been most frequently studied in solid cancers, although no mechanism has yet been proposed to link CD133 expression with the CSC phenotype. Some inconsistencies between published data can be ascribed to different analytical tools as well as methodological limitations and pitfalls, highlighted in the present review. Therefore, a comprehensive overview on the current state of knowledge in this growing and exciting field with an emphasis on the most recent studies is presented. We highlight the link between the tumour microenvironment, tumour cell plasticity, and CD133 expression, and evaluate the utility of CD133 expression as a prognostic marker. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Get access to the full text of this article

Ancillary